Latest gross profit for CCEL: $24M, below the Healthcare sector average of $67B.
Get informed when a big investor buys or sells
+ FollowAs of May 31, 2026
Trailing 12 months ending May 31, 2026
As of the most recent data (May 2026), CCEL shows a gross profit of $24M. That compares with $24M in the prior-year period — down 1.3% year over year. That is below the Healthcare sector average of $67B. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, CCEL's gross profit is now $24M (was $24M) — a 1.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Cryo-Cell International is outperforming or lagging.
The Healthcare sector average gross profit is about $67B. Cryo-Cell International is at $24M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how CCEL stacks up against individual peers as well.
Tracking CCEL's gross profit over time shows whether Cryo-Cell International is scaling, shrinking, or reshaping that part of the business. The current reading is $24M That compares with $24M in the prior-year period — down 1.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this gross profit page, Stockcircle has Cryo-Cell International's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect gross profit (currently $24M) with ownership activity and broader fundamentals.